Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.34 USD
-0.21 (-2.46%)
Updated May 24, 2024 04:00 PM ET
After-Market: $8.35 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Theravance Biopharma, Inc. [TBPH]
Reports for Purchase
Showing records 21 - 40 ( 206 total )
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
2Q Sales Came Below Expectations But Yupelris Growth Indicators Remain Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Yupelri''s Indicators All Point Up; PT Up to $20; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Theravance Commits to Maximizing Value Creation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Yupelri Makes Further Strides with Ampreloxetine Offering Significant Upside Optionality; Price Target Up to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D